Top

Reactions Weekly

Published in:

01-05-2022 | Hepatitis | Case report

Regorafenib/sintilimab/sorafenib

Multiple toxicities: 5 case reports

Published in: Reactions Weekly | Issue 1/2022

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Huang J, et al. Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study. Journal of Hepatocellular Carcinoma 9: 157-170, 2022. Available from: URL: http://doi.org/10.2147/JHC.S353956

Title: Regorafenib/sintilimab/sorafenib
Multiple toxicities: 5 case reports
Publication date: 01-05-2022
Publisher: Springer International Publishing
Keywords: Hepatitis
Regorafenib
Sorafenib
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-14827-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Regorafenib/sintilimab/sorafenib

Multiple toxicities: 5 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Elasomeran

Multiple drugs

Metamfetamine/milrinone

Alteplase

Ranibizumab

Tozinameran